Adalimumab

Active ingredient description

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC₅₀ of 0.1-0.2 nM).

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

L04AB04

Adalimumab

L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

Discover more medicines within L04AB04

Medicines

Adalimumab is the active ingredient of these drugs:

AMGEVITA

Australia Austria Brazil Cyprus Ecuador

AMSPARITY

Austria Estonia Ireland Lithuania Poland

CYLTEZO

Estonia Lithuania

HADLIMA

Australia

HALIMATOZ

Austria Estonia Lithuania Poland

HEFIYA

Austria Estonia Ireland Lithuania Poland

HUKYNDRA

Estonia Ireland Poland

HULIO

Austria Ecuador Estonia Finland France

HUMIRA

Australia Austria Brazil Canada Cyprus

HYRIMOZ

Australia Austria Brazil Cyprus Ecuador

IDACIO

Australia Austria Brazil Cyprus Ecuador

IMRALDI

Austria Cyprus Estonia Finland France

KROMEYA

Estonia Lithuania Poland

LIBMYRIS

Estonia Ireland Poland

LIDAX

Ecuador

SOLYMBIC

Estonia Lithuania

XILBRILADA

Brazil

YUFLYMA

Estonia Finland Germany Ireland Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

HUMIRA 80mg Solution for injection in pre-filled syringe / pen